Role of IgD in prevention and treatment of SARS CoV-2 infection “The Hidden Soldier" | ||||
| Microbial Biosystems | ||||
| Article 13, Volume 5, Issue 1, June 2020, Page 108-114 PDF (384.05 K) | ||||
| Document Type: Reviews | ||||
| DOI: 10.21608/mb.2020.33453.1019 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Donia Sheir  
| ||||
| Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Researches Division, National Research Centre, Dokki, 12622, Egypt. | ||||
| Abstract | ||||
| COVID-19 presents varied clinical features, ranging from asymptomatic, mild, to acute respiratory distress syndrome (ARDS). People of any age can be infected by the novel coronavirus but some people are at more risk than others of becoming seriously ill with COVID-19. Older people, and people with pre-existing medical conditions (such as asthma, diabetes, and heart disease) appear to be more vulnerable developing severe or even lethal illness. Children can be infected with SARS-CoV-2, and become ill with COVID-19. However, they appear to be less susceptible to infection than adults and their symptoms are generally milder. Immunoglobulin D (IgD) has remained an enigmatic antibody class since its discovery more than 50 years ago. The function of secreted IgD has been a longstanding puzzle in immunology. In this pandemic, it is the proper time to rediscover its role and find additional therapy to vaccine. In this article I will review IgD discovery, its role in immunity, its concentration in some groups and their susceptibility to infection with COVID 19. | ||||
| Keywords | ||||
| antibody therapy; COVID 19 vaccine alternative; Recombinant monoclonal antibodies (rAbs) | ||||
|
Statistics Article View: 571 PDF Download: 759 |
||||
